表紙:世界のがん遺伝子治療市場(2021年-2025年)
市場調査レポート
商品コード
982391

世界のがん遺伝子治療市場(2021年-2025年)

Global Cancer Gene Therapy Market 2021-2025

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.65円
世界のがん遺伝子治療市場(2021年-2025年)
出版日: 2021年01月08日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のがん遺伝子治療の市場規模は、予測期間中に20%のCAGRで推移し、2021年から2025年の間に29億6000万米ドル成長する見込みです。市場は、従来の癌治療の副作用、癌治療のための遺伝子治療に関連する利益、および癌治療の需要を後押しする癌の有病率の上昇によって推進されています。

当レポートでは、がん遺伝子治療市場を調査し、市場概要、市場の成長要因および阻害要因の分析、治療別・地域別の市場規模の推移と予測、ベンダー分析、市場機会など、包括的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模2020
  • 市場の見通し:2020年から2025年の予測

ファイブフォース分析

治療別市場セグメンテーション

  • 市場セグメンテーション
  • 治療別比較
  • 腫瘍溶解性ウイルス療法-市場規模と予測(2020年~2025年)
  • 遺伝子導入-市場規模と予測(2020年~2025年)
  • 遺伝子誘導免疫療法-市場規模と予測(2020年~2025年)
  • 治療別市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米-市場規模と予測(2020年~2025年)
  • 欧州-市場規模と予測(2020年~2025年)
  • アジア-市場規模と予測(2020年~2025年)
  • その他の地域-市場規模と予測(2020年~2025年)
  • 主要国
  • 地域の市場機会
  • 成長要因-需要主導の成長
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • ベンダー情勢
  • 創造的破壊の状況

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Adaptimmune Therapeutics plc
  • Advantagene Inc.
  • Amgen Inc.
  • Anchiano Therapeutics Ltd.
  • bluebird bio Inc.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono)
  • ZIOPHARM Oncology Inc.

付録

目次
Product Code: IRTNTR46595

Technavio has been monitoring the cancer gene therapy market and it is poised to grow by $ 2.96 bn during 2021-2025 progressing at a CAGR of 20% during the forecast period. Our report on cancer gene therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the side effects of traditional cancer treatments, benefits associated with gene therapy for cancer treatment and the rising prevalence rate of cancer boosting the demand for cancer therapeutics. In addition, the side effects of traditional cancer treatments is anticipated to boost the growth of the market as well.

The cancer gene therapy market analysis includes application segments and geographical landscapes.

Technavio's cancer gene therapy market is segmented as below:

By Application

  • Oncolytic virotherapy
  • Gene transfer
  • Gene-induced immunotherapy

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising partnerships and collaborations as one of the prime reasons driving the cancer gene therapy market growth during the next few years. Also, favorable government regulations for gene therapy programs and rapid growth potential in developing economies will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on cancer gene therapy market covers the following areas:

  • Cancer gene therapy market sizing
  • Cancer gene therapy market forecast
  • Cancer gene therapy market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer gene therapy market vendors that include Adaptimmune Therapeutics plc, Advantagene Inc., Amgen Inc., Anchiano Therapeutics Ltd., bluebird bio Inc., GlaxoSmithKline Plc, Merck KGaA, Shanghai Sunway Biotech Co. Ltd., Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono), and ZIOPHARM Oncology Inc. . Also, the cancer gene therapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Therapy

  • Market segments
  • Comparison by Therapy
  • Oncolytic virotherapy - Market size and forecast 2020-2025
  • Gene transfer - Market size and forecast 2020-2025
  • Gene-induced immunotherapy - Market size and forecast 2020-2025
  • Market opportunity by Therapy

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - Demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Adaptimmune Therapeutics plc
  • Advantagene Inc.
  • Amgen Inc.
  • Anchiano Therapeutics Ltd.
  • bluebird bio Inc.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono)
  • ZIOPHARM Oncology Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Other1 - Market share 2020-2025 (%)
  • 22: Comparison by Other1
  • 23: Oncolytic virotherapy - Market size and forecast 2020-2025 ($ million)
  • 24: Oncolytic virotherapy - Year-over-year growth 2020-2025 (%)
  • 25: Gene transfer - Market size and forecast 2020-2025 ($ million)
  • 26: Gene transfer - Year-over-year growth 2020-2025 (%)
  • 27: Gene-induced immunotherapy - Market size and forecast 2020-2025 ($ million)
  • 28: Gene-induced immunotherapy - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Other1
  • 30: Customer landscape
  • 31: Market share by geography 2020-2025 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2020-2025 ($ million)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ million)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: Asia - Market size and forecast 2020-2025 ($ million)
  • 38: Asia - Year-over-year growth 2020-2025 (%)
  • 39: ROW - Market size and forecast 2020-2025 ($ million)
  • 40: ROW - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Adaptimmune Therapeutics plc - Overview
  • 50: Adaptimmune Therapeutics plc - Product and service
  • 51: Adaptimmune Therapeutics plc - Key offerings
  • 52: Adaptimmune Therapeutics plc - Key customers
  • 53: Adaptimmune Therapeutics plc - Segment focus
  • 54: Advantagene Inc. - Overview
  • 55: Advantagene Inc. - Product and service
  • 56: Advantagene Inc. - Key offerings
  • 57: Advantagene Inc. - Key customers
  • 58: Advantagene Inc. - Segment focus
  • 59: Amgen Inc. - Overview
  • 60: Amgen Inc. - Business segments
  • 61: Amgen Inc. - Key offerings
  • 62: Amgen Inc. - Key customers
  • 63: Amgen Inc. - Segment focus
  • 64: Anchiano Therapeutics Ltd. - Overview
  • 65: Anchiano Therapeutics Ltd. - Business segments
  • 66: Anchiano Therapeutics Ltd. - Key offerings
  • 67: Anchiano Therapeutics Ltd. - Key customers
  • 68: Anchiano Therapeutics Ltd. - Segment focus
  • 69: bluebird bio Inc. - Overview
  • 70: bluebird bio Inc. - Business segments
  • 71: bluebird bio Inc. - Key offerings
  • 72: bluebird bio Inc. - Key customers
  • 73: bluebird bio Inc. - Segment focus
  • 74: GlaxoSmithKline Plc - Overview
  • 75: GlaxoSmithKline Plc - Business segments
  • 76: GlaxoSmithKline Plc - Key offerings
  • 77: GlaxoSmithKline Plc - Key customers
  • 78: GlaxoSmithKline Plc - Segment focus
  • 79: Merck KGaA - Overview
  • 80: Merck KGaA - Business segments
  • 81: Merck KGaA - Key offerings
  • 82: Merck KGaA - Key customers
  • 83: Merck KGaA - Segment focus
  • 84: Shanghai Sunway Biotech Co. Ltd. - Overview
  • 85: Shanghai Sunway Biotech Co. Ltd. - Product and service
  • 86: Shanghai Sunway Biotech Co. Ltd. - Key offerings
  • 87: Shanghai Sunway Biotech Co. Ltd. - Key customers
  • 88: Shanghai Sunway Biotech Co. Ltd. - Segment focus
  • 89: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) - Overview
  • 90: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) - Product and service
  • 91: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) - Key offerings
  • 92: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) - Key customers
  • 93: Sibiono GeneTech Co. Ltd. Shenzhen (Sibiono) - Segment focus
  • 94: ZIOPHARM Oncology Inc. - Overview
  • 95: ZIOPHARM Oncology Inc. - Product and service
  • 96: ZIOPHARM Oncology Inc. - Key offerings
  • 97: ZIOPHARM Oncology Inc. - Key customers
  • 98: ZIOPHARM Oncology Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations